Latest News - Multiple Sclerosis & Immune Disorders

Thursday, September 13, 2018

Fingolimod Effective for Treating Pediatric Patients with Multiple Sclerosis

Complete results from landmark phase 3 PARADIGMS clinical trial (NCT01892722) were published in the New England Journal of Medicine (September 12, 2018). The PARADIGMS trial is the first-ever complete…

Read the full story

Wednesday, August 29, 2018

Ibudilast Decreases Rate of Brain Atrophy in Progressive MS by 48%

Definitive results of a phase 2 study published in the New England Journal of Medicine, show that treatment of patients with progressive multiple sclerosis (MS) ibudilast (MN166; MediciNova, La Jolla,…

Read the full story

Tuesday, August 21, 2018

New Type of Multiple Sclerosis Identified

Researchers at the Cleveland Clinic have published findings in Lancet Neurology:(August 21, 2018) of a new subtype of multiple sclerosis, providing further understanding of the heterogenous …

Read the full story

Wednesday, August 08, 2018

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of persons with schizophrenia. …

Read the full story

Tuesday, July 31, 2018

New Drug Application for Cladribine Filed and Accepted

Cladribine (Mavenclad; EMD Serono, Rockland, MA) is an investigational oral therapy for patients with relapsing forms of multiple sclerosis (MS). The drug has proposed dosing of a maximum of 20 days o…

Read the full story

Monday, July 30, 2018

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safely in 5 persons with mild-…

Read the full story

Tuesday, July 10, 2018

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal Neuroimaging, regarding …

Read the full story

Thursday, June 28, 2018

Cladribine Tablets Showing Efficacy in Clinical Trials for Patients With Highly Active Multiple Sclerosis

At the recent CMSC meeting (Nashville, May 30-June 2, 2018)- data from clinical trials from the CLARITY trial of cladribine tablets (investigational in US, marketed as Mavenclad in Europe; EMD Serono,…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Friday, June 01, 2018

Results for Cladribine For MS Presented at CMSC

Data on use of cladribine tablets (EMD Serono, Rockland, MA) for treatment of relapsing multiple sclerosis (MS) were presented at the Consortium of Multiple Sclerosis Centers (CMSC) meeting in Nashvil…

Read the full story

Wednesday, April 25, 2018

Ocrelizumab Delays Cognitive Decline and Reduces Disease Activity and Disability Progression in Patients With MS

New data on ocrelizumab (OCREVUS; Genentech, South San Francisco, CA) were presented at the American Academy of Neurology this week, including results from 4 years of continuous treatment of patients …

Read the full story

Monday, April 23, 2018

New AAN Guideline: Patients With Multiple Sclerosis Should Start Treatment Early

The American Academy of Neurology (AAN) has released a new guideline for treating patients with multiple sclerosis (MS), which is endorsed by both the National Multiple Sclerosis Society and the Multi…

Read the full story

Monday, April 16, 2018

New Data on Ocrelizumab

Researchers will be presenting, at the upcoming American Academy of Neurology (AAN) meeting beginning on April 21st, 2018, new data on the use of ocrelizumab (OCREVUS; Genentech, San Francisco, CA), w…

Read the full story

Thursday, March 22, 2018

Phase 3 Clinical Trial Shows Siponimod Significantly Improved Outcomes in Patients With Secondary Progressive Multiple Sclerosis

Results from the phase 3 clinical trial, EXPAND, studying oral, once-daily siponimod (Novartis; East Hanover, NJ) for treatment of secondary progressive multiple sclerosis (SPMS) were published today …

Read the full story

Friday, March 16, 2018

Subcutaneous Immune Globulin Approved for Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Already approved in 51 countries for some immune deficiencies, subcutaneous immune globulin (IG) (Hizentra; King of Prussia, PA) has now been approved by the Food and Drug Administration (FDA) for tre…

Read the full story
Load More